Orchestra BioMed Holdings Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020
Market Capitalization	157	326	306	206	262
Market Cap Growth	-	6.75%	48.31%	-21.31%	-
Enterprise Value	72	240	234	201	236
PE Ratio	-6.64	-6.64	-9.10	-8.96	-12.27
PS Ratio	57.04	118.24	86.53	-263.60	45.94
PB Ratio	2.31	4.80	5.82	-10.42	-5.40
P/FCF Ratio	-7.06	-7.06	-10.23	-10.46	-9.80
P/OCF Ratio	-7.07	-7.07	-10.44	-10.61	-10.01
EV/Sales Ratio	25.91	87.11	66.18	-256.92	41.32
EV/EBITDA Ratio	-4.99	-4.99	-7.12	-9.17	-10.93
EV/EBIT Ratio	-4.89	-4.89	-6.96	-9.10	-10.87
EV/FCF Ratio	-5.20	-5.20	-7.82	-10.20	-8.82
Debt / Equity Ratio	0.02	0.02	0.23	-0.29	-0.19
Debt / EBITDA Ratio	-0.03	-0.03	-0.36	-0.26	-0.44
Debt / FCF Ratio	-0.04	-0.04	-0.40	-0.29	-0.35
Quick Ratio	7.82	7.82	4.52	0.90	2.50
Current Ratio	7.95	7.95	4.56	0.93	2.52
Asset Turnover	0.02	0.02	0.03	-0.01	-
Interest Coverage	-	-	-	-23.83	-
Return on Equity (ROE)	-58.30%	-58.30%	218.30%	675.20%	-
Return on Assets (ROA)	-41.50%	-41.50%	-25.50%	-18.40%	-
Return on Capital (ROIC)	-73.86%	-73.86%	-50.71%	154.53%	47.98%
Earnings Yield	-31.20%	-15.05%	-10.99%	-11.16%	-8.15%
FCF Yield	-29.35%	-14.16%	-9.77%	-9.56%	-10.20%
Buyback Yield / Dilution	-121.67%	-121.67%	-69.97%	-337.98%	-
Total Shareholder Return	-121.67%	-121.67%	-69.97%	-337.98%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).